Is Rezum (water‑vapor therapy) or TURP (transurethral resection of the prostate) indicated for a male patient with mild prostatomegaly and a post‑void residual volume of 207 mL (pre‑void volume 401 mL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Surgical Intervention is Indicated for This Patient with Significant Post-Void Residual

For a patient with mild prostatomegaly but significant post-void residual (PVR) of 207 mL (52% retention rate), surgical intervention is warranted, and either Rezūm or TURP can be offered depending on patient priorities regarding sexual function preservation versus treatment durability.

Clinical Context and Indication for Intervention

Your patient has a PVR of 207 mL out of 401 mL pre-void volume, representing a 52% retention rate. This is clinically significant elevated PVR (>200 mL is generally considered abnormal) and indicates bladder outlet obstruction requiring intervention beyond medical management alone. The "mild prostatomegaly" descriptor is less relevant than the functional impairment demonstrated by this elevated PVR.

Key point: Elevated baseline PVR is actually a predictor of treatment failure for Rezūm 1, so this patient characteristic must factor into your decision-making and counseling.

Treatment Options Based on 2023 EAU Guidelines

The 2023 European Association of Urology guidelines provide the framework 2:

TURP (Transurethral Resection of the Prostate)

  • Strong recommendation for moderate-to-severe LUTS with prostate size 30-80 mL 2
  • Gold standard with established long-term durability
  • Lower retreatment rates (1.5% in comparative studies) 2
  • Trade-off: Higher ejaculatory dysfunction rate (~50-57%) 2

Rezūm (Water Vapor Thermal Therapy)

  • May be offered per 2020 AUA guidelines for patients desiring preservation of erectile and ejaculatory function 3
  • Not specifically mentioned in the 2023 EAU surgical recommendations table, indicating it's a newer/alternative option
  • Advantage: Superior ejaculatory preservation (87.5% vs 50% for TURP) 4
  • Disadvantage: Higher retreatment rates (46.9% vs 15.6% for TURP at median 46-month follow-up) 4

Specific Recommendation for Your Patient

Given the elevated PVR of 207 mL, I recommend TURP as the primary option, with the following reasoning:

Why TURP is Preferred Here:

  1. PVR is a predictor of Rezūm failure: Elevated baseline PVR independently predicts treatment failure after Rezūm (OR 1.009 per mL increase, p<0.001) 1. Your patient's PVR of 207 mL places them at higher risk.

  2. Greater durability needed: With 52% retention rate, this patient needs definitive treatment. TURP provides more durable outcomes with lower retreatment rates (15.6% vs 46.9% for Rezūm) 4.

  3. Comparable functional outcomes: Both achieve similar IPSS improvement and Qmax improvement at 6-12 months 5, 4, but TURP maintains these gains longer-term.

When to Consider Rezūm Instead:

Offer Rezūm if the patient:

  • Is sexually active and prioritizes ejaculatory function preservation (87.5% preservation rate) 4
  • Accepts higher retreatment risk (approximately 20-47% may need additional intervention) 1, 4, 6
  • Has significant comorbidities making prolonged anesthesia risky 7, 8
  • Prefers outpatient procedure (90% of Rezūm done outpatient vs 0% TURP) 4

Important caveat: Even with Rezūm for retention cases, 12-20% remain catheter-dependent despite treatment 7, 8, though recent data shows 97% success in achieving spontaneous voiding 8.

Practical Algorithm for Decision-Making

Step 1: Assess sexual function priority

  • If ejaculatory function preservation is critical → Consider Rezūm
  • If durability/definitive treatment is priority → TURP

Step 2: Evaluate surgical risk

  • High anesthesia risk, anticoagulation, bleeding risk → Rezūm safer 8
  • Standard surgical candidate → TURP preferred given PVR

Step 3: Counsel on retreatment expectations

  • TURP: ~15% retreatment rate at 4 years
  • Rezūm: ~20-47% retreatment rate at 3-4 years 1, 4, 6

Step 4: Consider prostate size

  • If prostate <30 mL → Transurethral incision of prostate (TUIP) per guidelines 2
  • If 30-80 mL → TURP or Rezūm both appropriate
  • If >80 mL → Enucleation procedures (HoLEP) 2

Critical Pitfalls to Avoid

  1. Don't dismiss the elevated PVR: The "mild prostatomegaly" may be misleading—the functional obstruction (52% retention) is what matters for morbidity.

  2. Don't offer Rezūm without discussing retreatment risk: With this patient's elevated PVR, the retreatment likelihood is substantial and must be disclosed upfront.

  3. Don't delay intervention: PVR >200 mL increases risk of bladder decompensation, recurrent UTIs, and upper tract deterioration.

  4. Avoid Rezūm if middle lobe present and considering alternatives: While Rezūm can treat median lobes 7, prostatic urethral lift (PUL) cannot and requires absence of obstructive middle lobe 3.

References

Related Questions

Is Rezum or transurethral resection of the prostate (TURP) indicated after failed medical therapy in a male patient with mild prostatomegaly and significant post‑void residual urine (pre‑void volume 401 mL, post‑void residual 207 mL)?
Is Rezum water‑vapor thermal therapy indicated for a patient with mild benign prostatic hyperplasia (BPH) and prostatomegaly who has a pre‑void urine volume of 401 mL and a post‑void residual urine volume of 207 mL?
What antibiotics are appropriate for an 89-year-old man with benign prostatic hyperplasia who has a urinary tract infection?
In an 82‑year‑old male with severe left knee osteoarthritis, enlarged prostate causing obstructive uropathy, stage 4 chronic kidney disease, hypertension, macrocytic anemia, and hypothyroidism, should prostate‑relieving surgery be performed before total knee replacement?
How should I approach a 65-year-old male presenting with abdominal heaviness and loss of appetite for 3–4 months, who has normal oxygen saturation, normal heart rate, stage 1 hypertension, and ultrasound findings of grade 1 fatty liver, a left renal calculus with concretions, and grade 1 prostatomegaly?
Should I consult General Surgery for a transient intussusception?
For a severe carbapenem‑resistant Gram‑negative infection, especially metallo‑β‑lactamase‑producing, should I use colistin or aztreonam plus ceftazidime‑avibactam (Zerbaxa) as the preferred therapy?
How can I determine from an antimicrobial susceptibility report whether a patient has carbapenem‑resistant Enterobacterales (CRE)?
What is the appropriate heparin dose for flushing a subclavian port in adult patients without heparin allergy or bleeding risk?
Is Rezum or transurethral resection of the prostate (TURP) indicated after failed medical therapy in a male patient with mild prostatomegaly and significant post‑void residual urine (pre‑void volume 401 mL, post‑void residual 207 mL)?
Should I administer intravenous mannitol for acute intracranial hypertension in a patient with tuberculous meningitis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.